|
We report the results of an open trial of botulinum toxin (Botox) in the treatment of 46 patients with cranial dystonia (38 patients with blepharospasm and 8 patients with Meige syndrome). The average age of the patients was 55,8 years, and duration of symptoms was 10,6 years. The blepharospasm involuntary movement (BIM) scale was used to asses clinical severity at baseline before BoNT/A injections and at two follow up visits after 6 and 12 weeks covering one BoNT/A treatment period with maximum effect size at the firs follow up.The average latency from injection to response was 6,8 days, and the average duration of maximum improvement was 10,5 weeks. Local complications, lasting an average of 20,6 days noted in three patients, consisting of ptosis. Botulinum toxin treatment led to a significant improvement of clinical scale assessed with the blepharospasm involuntary scale (BIM). The results of this study indicate, that botulinum toxin injection is safe and effective for the long-term management of focal cranial dystonia.
Keywords:
blepharospasm, Meige syndrome, botulinum toxin, blepharospasm involuntary movement scale
|
